» Articles » PMID: 38334678

Glymphatic System Pathology and Neuroinflammation As Two Risk Factors of Neurodegeneration

Overview
Journal Cells
Publisher MDPI
Date 2024 Feb 9
PMID 38334678
Authors
Affiliations
Soon will be listed here.
Abstract

The key to the effective treatment of neurodegenerative disorders is a thorough understanding of their pathomechanism. Neurodegeneration and neuroinflammation are mutually propelling brain processes. An impairment of glymphatic system function in neurodegeneration contributes to the progression of pathological processes. The question arises as to how neuroinflammation and the glymphatic system are related. This review highlights the direct and indirect influence of these two seemingly independent processes. Protein aggregates, a characteristic feature of neurodegeneration, are correlated with glymphatic clearance and neuroinflammation. Glial cells cannot be overlooked when considering the neuroinflammatory processes. Astrocytes are essential for the effective functioning of the glymphatic system and play a crucial role in the inflammatory responses in the central nervous system. It is imperative to acknowledge the significance of AQP4, a protein that exhibits a high degree of polarization in astrocytes and is crucial for the functioning of the glymphatic system. AQP4 influences inflammatory processes that have not yet been clearly delineated. Another interesting issue is the gut-brain axis and microbiome, which potentially impact the discussed processes. A discussion of the correlation between the functioning of the glymphatic system and neuroinflammation may contribute to exploring the pathomechanism of neurodegeneration.

Citing Articles

Brain Glycogen-Its Metabolic Role in Neuronal Health and Neurological Disorders-An Extensive Narrative Review.

Beltran-Velasco A Metabolites. 2025; 15(2).

PMID: 39997753 PMC: 11857135. DOI: 10.3390/metabo15020128.


Structural and functional brain correlates of the neutrophil- and monocyte-to-lymphocyte ratio in neuropsychiatric disorders.

McIntosh R Brain Behav Immun Health. 2025; 43:100940.

PMID: 39877850 PMC: 11773257. DOI: 10.1016/j.bbih.2024.100940.


Machine Learning Recognizes Stages of Parkinson's Disease Using Magnetic Resonance Imaging.

Chudzik A Sensors (Basel). 2025; 24(24.

PMID: 39771887 PMC: 11679256. DOI: 10.3390/s24248152.


Evaluating the robustness of DTI-ALPS in clinical context: a meta-analytic parallel on Alzheimer's and Parkinson's diseases.

Costa T, Manuello J, Premi E, Mattioli I, Lasagna L, Lahoz C Sci Rep. 2024; 14(1):26381.

PMID: 39487289 PMC: 11530450. DOI: 10.1038/s41598-024-78132-9.


The selective butyrylcholinesterase inhibitor UW-MD-95 shows symptomatic and neuroprotective effects in a pharmacological mouse model of Alzheimer's disease.

Carles A, Hoffmann M, Scheiner M, Crouzier L, Bertrand-Gaday C, Chatonnet A CNS Neurosci Ther. 2024; 30(6):e14814.

PMID: 38887858 PMC: 11183908. DOI: 10.1111/cns.14814.


References
1.
Li J, Shui X, Sun R, Wan L, Zhang B, Xiao B . Microglial Phenotypic Transition: Signaling Pathways and Influencing Modulators Involved in Regulation in Central Nervous System Diseases. Front Cell Neurosci. 2021; 15:736310. PMC: 8476879. DOI: 10.3389/fncel.2021.736310. View

2.
Rezai-Zadeh K, Gate D, Town T . CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease?. J Neuroimmune Pharmacol. 2009; 4(4):462-75. PMC: 2773117. DOI: 10.1007/s11481-009-9166-2. View

3.
Portincasa P, Bonfrate L, Vacca M, De Angelis M, Farella I, Lanza E . Gut Microbiota and Short Chain Fatty Acids: Implications in Glucose Homeostasis. Int J Mol Sci. 2022; 23(3). PMC: 8835596. DOI: 10.3390/ijms23031105. View

4.
Vogt N, Kerby R, Dill-McFarland K, Harding S, Merluzzi A, Johnson S . Gut microbiome alterations in Alzheimer's disease. Sci Rep. 2017; 7(1):13537. PMC: 5648830. DOI: 10.1038/s41598-017-13601-y. View

5.
Sofroniew M, Vinters H . Astrocytes: biology and pathology. Acta Neuropathol. 2009; 119(1):7-35. PMC: 2799634. DOI: 10.1007/s00401-009-0619-8. View